Back HCV Treatment

Gilead Announces Generic Licensing Agreements for Hepatitis C Drug Sofosbuvir

Gilead Sciences announced this week that it has granted a license to 7 generic drug companies in India to produce cheaper versions of its groundbreaking hepatitis C polymerase inhibitor sofosbuvir (Sovaldi) and its forthcoming sofosbuvir/ledipasvir coformulation for use in more than 90 developing countries.


Read more: